Synopsis
Confirm dangerous triglyceride elevation, prevent and recognise acute pancreatitis, reverse secondary drivers rapidly, and coordinate dietary, diabetes, lipid and genetic specialist treatment.
- Triglycerides between 10 and 20 mmol/L require a fasting repeat after at least five days but within two weeks, plus immediate review of secondary causes.
- Seek specialist advice if the repeat fasting concentration remains above 10 mmol/L; refer urgently above 20 mmol/L when alcohol or poor glycaemic control does not explain it.
- Acute pancreatitis risk rises substantially with severe triglyceride elevation, but pain and organ dysfunction determine emergency care rather than a lipid number alone.
- Uncontrolled diabetes or DKA, alcohol, pregnancy, obesity, hypothyroidism, renal disease and medicines are common reversible or aggravating factors.
- Eruptive xanthomata, lipaemic plasma, hepatosplenomegaly or lipaemia retinalis can indicate chylomicronaemia and should prompt specialist genetic consideration.
- Immediately stop alcohol and obtain dietetic advice on a temporary very-low-fat, nutritionally complete plan when chylomicrons create pancreatitis risk.
- Control marked hyperglycaemia promptly; intravenous insulin belongs to DKA, hyperglycaemic crisis or specialist acute-pancreatitis protocols, not an automatic response to every high triglyceride result.
- Fenofibrate is often used under lipid-specialist advice after renal, hepatic, gallbladder, interaction and pregnancy review; gemfibrozil is hazardous with statins.
- Statins reduce cardiovascular risk but do not lower severe chylomicron-rich triglycerides rapidly enough to be the sole pancreatitis-prevention strategy.
- Plasma exchange and other intensive therapies are not routine; critical care, lipid and pancreatitis specialists select them for exceptional severe or refractory cases.
- Once the acute risk falls, prevent recurrence by sustaining glycaemic control, alcohol abstinence where causal, dietetic follow-up, weight care and a family or genetic plan when indicated.
Key red flags
Persistent severe epigastric pain radiating to the back with vomiting, ileus, tachycardia or hypotension requires emergency assessment; the triglyceride may fall after fasting, so obtain an early sample.
Polyuria, thirst, weight loss, ketones, acidosis or very high glucose identifies insulin deficiency as a major cause; DKA requires immediate validated emergency treatment.
Investigation priorities
Confirm severe elevation after a high non-fasting result and quantify immediate risk.
Management branches
A non-fasting triglyceride concentration is between 10 and 20 mmol/L.
- Ask immediately about abdominal pain, vomiting, alcohol, diabetes symptoms, pregnancy and triglyceride-raising medicines, sending symptomatic patients to acute assessment.
- Arrange a fasting repeat after at least five days and within two weeks while beginning correction of obvious secondary drivers and giving alcohol and dietary safety advice.
- Seek lipid-specialist input if fasting triglycerides remain above 10 mmol/L, and escalate urgency if values rise, symptoms develop or pregnancy complicates care.
Key medicines
Fenofibrate for severe hypertriglyceridaemiaA common adult oral regimen is 160 mg once daily for the relevant tablet formulation; exact dose varies by product and renal function, so verify the current BNF and specialist plan.Avoid severe renal or hepatic disease, gallbladder disease and pregnancy unless specialist-directed. Review creatinine, liver and muscle symptoms; statin combination increases myopathy risk, and formulations are not milligram-equivalent.
Insulin for DKA or severe hyperglycaemiaUse the current fixed-rate intravenous insulin and fluid protocol for DKA, or the specialist inpatient glycaemic regimen for another hyperglycaemic emergency, with hourly glucose and electrolyte monitoring.Do not run insulin solely to normalise triglycerides without specialist indication. Prevent hypoglycaemia and hypokalaemia, add glucose when protocol requires and never omit essential basal insulin in type 1 diabetes.